Abbvie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Oncology and Immunology
Shots:
- AbbVie & Neomorph have partnered in a collaboration & option-to-license deal to develop molecular glue degraders for oncology & immunology, using Neomorph's molecular glue discovery
- As per the terms, Neomorph will receive upfront & is eligible for ~$1.64B in future option fee & milestones, plus net sales-based royalties
- Molecular glue degraders are small molecules that selectively target & trigger the degradation of proteins responsible for cancer growth or immune system dysregulation
Ref: Prnewswire | Image: AbbVie & Neomorph
Related News:- AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
